Lembas has built a proprietary computational AI discovery platform that rapidly screens, analyzes and designs food-grade bioactive peptides, with an initial product called GLP-1 Edge designed to enhance the body's own GLP-1 response. GLP-1 Edge has been demonstrated in cell and animal models to stimulate GLP-1 secretion to blood and is shown in multiple consumer formats including gummies, powder, and capsules. The company positions the ingredient for integration into bars, shakes, snacks, beverages and supplements to address the global weight management market. Lembas emphasizes food-as-medicine applications and plans to scale commercialization and deepen commercial agreements across the ingredients, food and supplements value chain. Backed by university-patented pending technology, the team combines entrepreneurs and interdisciplinary scientists with executive experience from leading food companies. Founded in 2024 and based in Tel Aviv, Israel, Lembas emerged from stealth following its early validation.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2025